CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.
Trial registration: ClinicalTrials.gov NCT04213469 NCT04213469 NCT04185038 NCT04670068 NCT05241392 NCT04077866 NCT04662294.
Keywords: CAR-T cell; checkpoint; immunotherapy; review; tumor.
© 2022 The Author(s). Published by IMR Press.